Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4096825
Max Phase: Preclinical
Molecular Formula: C22H33NO4
Molecular Weight: 375.51
Molecule Type: Small molecule
Associated Items:
ID: ALA4096825
Max Phase: Preclinical
Molecular Formula: C22H33NO4
Molecular Weight: 375.51
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCC[C@H]1O[C@@H]1C(OC(=O)c1ccccc1)C(=O)NC(C)(C)C
Standard InChI: InChI=1S/C22H33NO4/c1-5-6-7-8-12-15-17-18(26-17)19(20(24)23-22(2,3)4)27-21(25)16-13-10-9-11-14-16/h9-11,13-14,17-19H,5-8,12,15H2,1-4H3,(H,23,24)/t17-,18+,19?/m1/s1
Standard InChI Key: YUELGOMGDYIAPF-YTYFACEESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 375.51 | Molecular Weight (Monoisotopic): 375.2410 | AlogP: 4.25 | #Rotatable Bonds: 10 |
Polar Surface Area: 67.93 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.69 | CX Basic pKa: | CX LogP: 5.14 | CX LogD: 5.14 |
Aromatic Rings: 1 | Heavy Atoms: 27 | QED Weighted: 0.38 | Np Likeness Score: 0.37 |
1. Dos Santos DA, Deobald AM, Cornelio VE, Ávila RMD, Cornea RC, Bernasconi GCR, Paixão MW, Vieira PC, Corrêa AG.. (2017) Asymmetric synthesis and evaluation of epoxy-α-acyloxycarboxamides as selective inhibitors of cathepsin L., 25 (17): [PMID:28720327] [10.1016/j.bmc.2017.06.048] |
2. Silva TL, Dos Santos DA, de Jesus HCR, Brömme D, Fernandes JB, Paixão MW, Corrêa AG, Vieira PC.. (2020) Green asymmetric synthesis of epoxypeptidomimetics and evaluation as human cathepsin K inhibitors., 28 (15): [PMID:32631567] [10.1016/j.bmc.2020.115597] |
Source(1):